In a clinical setting, miR-17/92 is up-regulated in early chronic-phase (CP), but not in blast-crisis (BC) CML CD34 (+) cells when compared with normal CD34 (+) cells. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.